Ilomedin 20

Ilomedin 20



Bayer HealthCare Pharma


Concise Prescribing Info
Iloprost trometamol
Relief of symptoms of advanced thromboangiitis obliterans (Buerger's disease) w/ critical limb ischemia in cases where revascularization is not indicated. Relief of symptoms of severe peripheral arterial occlusive disease (PAOD stage III, IV), particularly those at risk of amputation & in whom surgery or angioplasty is not possible. Relief of symptoms of severe disabling Raynaud's phenomenon unresponsive to other therapies.
Dosage/Direction for Use
Adjust dose according to individual tolerability w/in the range of 0.5-2 ng/kg body wt/min over 6 hr daily by IV infusion for up to 4 wk. Duration of treatment for Raynaud's phenomenon: 3-5 days.
Active peptic ulcers, trauma, intracranial hemorrhage; severe CHD or unstable angina; MI w/in the last 6 mth; acute or chronic CHF; arrhythmia relevant to the prognosis; suspected pulmonary congestion. Pregnancy & lactation.
Special Precautions
Hypotension. Possible orthostatic hypotension. Monitor patients w/ significant heart disease. Avoid contact w/ skin or mucous membranes.
Adverse Reactions
Flush, headache, GI symptoms, sweating, nervous system & psychiatric disorders, infusion site reactions.
Drug Interactions
β-blockers, Ca antagonists & vasodilators; ACE inhibitors; heparin or coumarin-type anticoagulants; other platelet aggregation inhibitors, phosphodiesterase inhibitors & nitrovasodilators.
ATC Classification
B01AC11 - iloprost ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Ilomedin 20 infusion 20 mcg/mL
1 mL x 5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in